알레르기 진단 시장 : 기회, 성장 촉진요인, 산업 동향 분석(2025-2034년)

The Global Allergy Diagnostics Market was valued at USD 6.6 billion in 2024 and is projected to expand at a CAGR of 10.9% between 2025 and 2034, driven by an increasing prevalence of allergic conditions such as asthma, rhinitis, and food allergies. With changing lifestyles, rising pollution levels, and growing environmental triggers, the demand for accurate and efficient allergy testing solutions has never been higher. The rapid advancements in diagnostic technologies, including multiplex assays and immunoassays, are revolutionizing allergy testing by improving precision, efficiency, and patient comfort. These innovations allow healthcare providers to detect a broader range of allergens with enhanced speed and accuracy, ensuring timely and effective patient management.

The market expansion is also fueled by the increasing economic burden of allergic diseases, which affect millions of individuals worldwide. Healthcare providers and research institutions are actively investing in advanced diagnostic tools to improve early detection and personalized treatment approaches. The growing awareness about the benefits of early diagnosis, coupled with rising healthcare expenditures, is further driving demand for sophisticated allergy testing solutions. In addition, the increasing adoption of automation in laboratories is streamlining allergy diagnostics, reducing human error, and enhancing test reproducibility, making allergy testing more accessible and reliable.

The allergy diagnostics market is classified by product and service into consumables, instruments, and services. Among these, consumables are expected to dominate the market, growing at a CAGR of 10.8% and reaching USD 10.2 billion by 2034. The rising prevalence of allergic diseases, combined with their substantial healthcare costs, is fueling demand for consumables, including reagents and test kits. With allergies becoming more widespread due to environmental changes, the need for advanced diagnostic solutions that offer accurate allergen identification is increasing.

In terms of test type, the market is categorized into in vivo and in vitro tests. The in vivo segment is projected to contribute significantly to market expansion, growing at a CAGR of 10.6% and surpassing USD 9.6 billion by 2034. Skin prick tests and intradermal tests remain essential for diagnosing various allergies, as they provide quick, reliable results. Their affordability, accuracy, and ease of use in clinical settings make them a preferred choice among healthcare professionals. These tests are particularly effective in detecting allergies caused by environmental factors, food, and insect venom, further driving their adoption.

The U.S. allergy diagnostics market, valued at USD 2.3 billion in 2024, is expected to grow at a CAGR of 10.2% between 2025 and 2034. The country's increasing rates of allergic conditions, heightened awareness among healthcare providers and patients, and the growing shift toward personalized treatment approaches are key factors propelling market growth. The rising need for accurate diagnostic tools, combined with strong healthcare infrastructure and technological advancements, is further strengthening the market outlook. As allergy-related disorders continue to rise, the U.S. market is poised for substantial expansion, providing lucrative opportunities for diagnostic manufacturers and healthcare providers alike.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence and high economic burden of allergic diseases
    • 3.2.1.2 Growing pollution levels coupled with rise in respiratory disorders
    • 3.2.1.3 Rise in funding for allergy diagnostics companies
    • 3.2.1.4 Pediatric allergy awareness
    • 3.2.1.5 Technological advancements in new products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of allergy diagnostic instrument
    • 3.2.2.2 Limited awareness related to allergic diseases
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Gap analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Future market trends
• 3.10 Value chain analysis
• 3.11 Innovations in allergy diagnostics and management
• 3.12 The future of food allergy diagnosis
• 3.13 AI-enhanced allergy diagnostics

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 — 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
• 5.3 Instruments
• 5.4 Services

Chapter 6 Market Estimates and Forecast, By Test Type, 2021 — 2034 ($ Mn)

• 6.1 Key trends
• 6.2 In Vivo
  • 6.2.1 Skin prick tests
  • 6.2.2 Intradermal skin test
  • 6.2.3 Other in vivo test types
• 6.3 In Vitro

Chapter 7 Market Estimates and Forecast, By Allergen, 2021 — 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Inhaled allergens
• 7.3 Food allergens
• 7.4 Drug allergens
• 7.5 Other allergens

Chapter 8 Market Estimates and Forecast, By End Use, 2021 — 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Diagnostic laboratories
• 8.3 Hospital-based laboratories
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 — 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 BIOMERIEUX
• 10.2 danaher
• 10.3 eurofins
• 10.4 EUROIMMUN
• 10.5 HITACHI
• 10.6 HOB
• 10.7 hycor
• 10.8 LINCOLN Diagnostics INC.
• 10.9 MINARIS Medical
• 10.10 NEOGEN CORPORATION
• 10.11 Omega DIAGNOSTICS GROUP PLC
• 10.12 r-biopharm
• 10.13 SIEMENS Healthcare Diagnostics
• 10.14 STALLERGENES
• 10.15 Thermo Fisher SCIENTIFIC